Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 8/2009

01-08-2009 | Original Article—Alimentary Tract

Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication

Authors: Katsunori Iijima, Tomoyuki Koike, Yasuhiko Abe, Nobuyuki Ara, Kaname Uno, Akira Imatani, Shuichi Ohara, Tooru Shimosegawa

Published in: Journal of Gastroenterology | Issue 8/2009

Login to get access

Abstract

Purpose

The measurement of serum pepsinogens is clinically useful to represent gastric acid secretion. Since both serum pepsinogens and gastric acid secretion are considerably altered by H. pylori eradication, the correlation between these two parameters could be different prior to and after eradication. In this study, we investigated the correlation between the two parameters prior to and after eradication.

Methods

One hundred eighteen H. pylori-positive patients with peptic ulcers or chronic gastritis were enrolled in this retrospective analysis. In all participants both the measurement of serum pepsinogens and the determination of gastric acid secretion were performed prior to and at 1 month after successful eradication. In 85 subjects, the same assessments were repeated at 7 months. Correlations between serum pepsinogens and gastric acid secretion were assessed using linear regression analysis.

Results

The pepsinogen I/II ratio (r = 0.56) was a better indicator of gastric acid secretion in H. pylori-infected subjects than pepsinogen I itself (r = 0.31). Eradication of H. pylori altered the association, causing pepsinogen I (r = 0.55) to become a better indicator of gastric acid secretion compared with the pepsinogen I/II ratio (r = 0.40) at 1 month after eradication, followed by similar tendencies at 7 months.

Conclusion

Using different serum biomarkers (pepsinogen I/II ratio prior to eradication or pepsinogen I after eradication), the measurement of serum pepsinogens is useful for predicting the individual gastric acid secretion level not only in H. pylori-infected subjects, but also in subjects with histories of eradication of the infection.
Literature
1.
2.
Fukao A, Tsubono Y, Tsuji I, Hisamichi S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer. 1995;60:45–8.PubMedCrossRef
3.
Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003;98:735–9.PubMedCrossRef
4.
Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999;44:693–7.PubMedCrossRef
5.
Samloff IM. Cellular localization of group I pepsinogen in human gastric mucosa by immunofluorescence. Gastroenterology. 1971;61:185–8.PubMed
6.
Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology. 1973;65:36–42.PubMed
7.
Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationship among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives with pernicious anemia. Gastroenterology. 1982;83:204–9.PubMed
8.
Borch K, Axelsson CK, Halgreen H, Nielson MD, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol. 1989;24:870–6.PubMedCrossRef
9.
Nakanome C, Akai H, Goto Y. Serum group I pepsinogen levels in patients with peptic ulcer and normal subjects. Tohoku J Exp Med. 1983;139:151–8.PubMedCrossRef
10.
Feldman M, Richardson CT, Lam SK, Samloff IM. Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in occidental and oriental duodenal ulcer patients. Gastroenterology. 1998;95:630–5.
11.
Samloff IM, Secrist DM, Passaro E. A study of relationship between serum group I pepsinogen levels and gastric acid secretion. Gastroenterology. 1975;69:1196–200.PubMed
12.
Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, et al. Serum pepsinogen as a screening test of extensive chronic gastritis. Gastroenterol Jpn. 1987;22:133–41.PubMed
13.
Haruma K, Yoshihara M, Sumii K, Tari A, Watanabe C, Kodoi A, et al. Gastric acid secretion, serum pepsinogen I, and serum gastrin in Japanese with gastric hyperplastic polyps or polypoid-type early gastric carcinoma. Scand J Gastroenterol. 1993;28:633–7.PubMedCrossRef
14.
Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut. 1997;41:452–8.
15.
Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990;50:4737–40.PubMed
16.
Siurala M, Varis K, Wiliasalo M. Studies of patients with atrophic gastritis: 10–15-year follow-up. Scand J Gastroenterol. 1966;1:40–8.PubMed
17.
Svendsen JH, Svendsen CD, Christiansen PM. Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand J Gastroenterol. 1986;21:16–20.PubMedCrossRef
18.
Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yashida H, Kawabe T, et al. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects. Gut. 2001;49:335–40.PubMedCrossRef
19.
Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2003;109:138–43.CrossRef
20.
Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori-negative and -positive Japanese subjects. J Gastroenterol. 2005;40:938–44.PubMedCrossRef
21.
Abe Y, Ohara S, Koike T, Sekine H, Iijima K, Kawamura M, et al. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett’s esophagus in Japan. Am J Gastroenterol. 2004;99:1213–21.PubMedCrossRef
22.
Koike T, Ohara S, Sekine H, Iijima K, Abe Y, Kato K, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut. 2001;49:330–4.PubMedCrossRef
23.
El-Omar EM, Penman I, Ardill JES, Chittajallu RS, Howie C, McColl KEL. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology. 1995;109:681–91.PubMedCrossRef
24.
El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997;113:15–24.PubMedCrossRef
25.
Iijima K, Ohara S, Sekine H, Koike T, Kato K, Asaki S, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut. 2000;46:20–6.PubMedCrossRef
26.
Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment Pharmacol Ther. 2004;19:1181–8.PubMedCrossRef
27.
Chittajallu RS, Dorrian CA, Ardill JE, McColl KE. Effect of Helicobacter pylori on serum pepsinogen I and plasma gastrin in duodenal ulcer patients. Scand J Gastroenterol. 1992;27:20–4.PubMedCrossRef
28.
Furuta T, Kaneko E, Baba S, Arai H, Futami H. Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori. Am J Gastroenterol. 1997;92:84–8.PubMed
29.
Gisbert JP, Boixeda D, Vila T, de Rafael L, Redondo C, Cantón R, et al. Verification of decreased basal and stimulated serum pepsinogen-I levels is a useful non-invasive method for determining the success of eradication therapy for Helicobacter pylori. Scand J Gastroenterol. 1996;31:103–10.PubMedCrossRef
30.
Koike T, Ohara S, Sekine H, Iijima K, Kato K, Toyota T, et al. Increased gastric acid secretion after H. pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther. 2001;15:813–20.PubMedCrossRef
31.
Iijima K, Ohara S, Sekine H, Koike T, Kubata Y, Kato K, et al. A new endoscopic method of gastric acid secretory testing. Am J Gastroenterol. 1998;93:2113–8.PubMedCrossRef
32.
Ichinose M, Miki K, Furihara C, Kageyama T, Hayashi R, Niwa H, et al. Radioimmunoassay of serum group I and group II pepsinogen in normal controls and patients with various disorders. Clin Chim Acta. 1982;126:183–91.PubMedCrossRef
33.
Yasunaga Y, Shinomura Y, Kanayama S, Miyazaki Y, Bonilla Palacios JJ, Matsuzawa Y. Serum pepsinogen I levels and acid secretion in Helicobacter pylori associated enlarged fold gastritis. Ital J Gastroenterol. 1995;28:457–61.
34.
Wagner S, Haruma K, Gladziwa U, Soudah B, Gebel M, Bleck J, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol. 1994;89:1211–8.PubMed
35.
Mossi S, Meyer-Wyss B, Renner EL, Merki H, Gamboni G, Beglinger C. Influence of Helicobacter pylori, sex, and age on serum gastrin and papsinogen concentrations in subjects without symptoms and patients with duodenal ulcers. Gut. 1993;34:752–6.PubMedCrossRef
36.
Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005;100:1037–42.PubMedCrossRef
37.
Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7.
38.
Kamada T, Hata J, Sugiu K, Kusunoki H, Ito M, Tanaka S, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005;21:1121–6.PubMedCrossRef
39.
Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536–40.PubMedCrossRef
40.
Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16:1923–32.PubMedCrossRef
41.
Shiotani A, Uedo N, Iishi H, Yoshiyuki Y, Ishii M, Manabe N, et al. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion. 2008;78:113–9.PubMedCrossRef
42.
Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K. et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42(Suppl 17):21–7.PubMedCrossRef
43.
Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:1442–7.PubMedCrossRef
44.
Vaira D, Vakil N, Rugge M, Gatta L, Ricci C, Menegatti M, et al. Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut. 2003;52:1543–7.PubMedCrossRef
45.
Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut. 2004;53:174–9.PubMedCrossRef
46.
Cremonini F, Di Caro S, Delgado-Aros S, Sepulveda A, Gasbarrini G, Gasbarrini A, et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;18:279–89.PubMedCrossRef
47.
Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. Helicobacter pylori eradication may induce de novo, but transient and mild, reflux esophagitis: prospective endoscopic evaluation. J Gastroenterol Hepatol. 2009;24:107–13.PubMedCrossRef
48.
Abe Y, Iijima K, Koike T, Asanuma K, Imatani A, Ohara S, et al. Barrett’s esophagus is characterized by the absence of Helicobacter pylori infection and high levels of serum pepsinogen I concentration in Japan. J Gastroenterol Hepatol. 2009;24:129–34.PubMedCrossRef
49.
Monkemuller K, Neumann H, Nocon M, Vieth M, Labenz J, Willich SN, et al. Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastro-oesophageal reflux disease: a matched case-control study. Aliment Pharmacol Ther. 2008;28:491–6.PubMedCrossRef
Metadata
Title
Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication
Authors
Katsunori Iijima
Tomoyuki Koike
Yasuhiko Abe
Nobuyuki Ara
Kaname Uno
Akira Imatani
Shuichi Ohara
Tooru Shimosegawa
Publication date
01-08-2009
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 8/2009
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0066-2

Other articles of this Issue 8/2009

Journal of Gastroenterology 8/2009 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B

Review

Asymmetrical circumferential distribution of esophagogastric junctional lesions: anatomical and physiological considerations

Review

Immune responses of TLR5+ lamina propria dendritic cells in enterobacterial infection

Original Article—Alimentary Tract

Can Western endoscopists identify the end of the lower esophageal palisade vessels as a landmark of esophagogastric junction?

Original Article—Alimentary Tract

The use of indigocarmine spray increases the colonoscopic detection rate of adenomas

Original Article—Liver, Pancreas, and Biliary Tract

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits